France drug regulator in January yanked Bayer's contraceptive Diane-35 off the market and insisted the European Medicines Agency investigate its off-label use as an acne treatment and its risks of blood clots. The EMA has done that and has come down in support of the drug, even for the off-label use.
Continued here:
EMA says Bayer’s Diane-35 has more benefit than risk
France drug regulator in January yanked Bayer's contraceptive Diane-35 off the market and insisted the European Medicines Agency investigate its off-label use as an acne treatment and its risks of blood clots. The EMA has done that and has come down in support of the drug, even for the off-label use.
More here:
EMA says Bayer’s Diane-35 has more benefit than risk
GlaxoSmithKline CFO Simon Dingemans?has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale.
Read more:
GSK tries novel approach in emerging markets: price cuts
GlaxoSmithKline CFO Simon Dingemans?has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale.
Go here to see the original:
GSK tries novel approach in emerging markets: price cuts
How much is a generic drug worth to a payer? More than ?350 million, for the U.K.'s National Health Service anyway. That's how much it saved during the first 12 months after Pfizer's Lipitor went off patent, the generic industry's trade association says.
Go here to see the original:
U.K. saves £1 million a day, thanks to generic Lipitor
How much is a generic drug worth to a payer? More than ?350 million, for the U.K.'s National Health Service anyway. That's how much it saved during the first 12 months after Pfizer's Lipitor went off patent, the generic industry's trade association says.
View post:
U.K. saves £1 million a day, thanks to generic Lipitor
Along with its partner, Astellas, Roche has won FDA approval for a new, first-line use for its lung cancer drug Tarceva in patients whose cancers test positive for specific mutations of the EGFR gene. Roche also got the nod for a diagnostic test to identify eligible patients.
Visit link:
Roche wins new targeted OK for Tarceva in EGFR-positive lung cancer
Along with its partner, Astellas, Roche has won FDA approval for a new, first-line use for its lung cancer drug Tarceva in patients whose cancers test positive for specific mutations of the EGFR gene. Roche also got the nod for a diagnostic test to identify eligible patients.
Go here to read the rest:
Roche wins new targeted OK for Tarceva in EGFR-positive lung cancer
Regeneron Pharmaceuticals ( $REGN ) is like a sports team on a streak that keeps bettors in the money by beating bookmaker odds time and again. This streak has gone uninterrupted for nearly two years. The maker of the eye drug Eylea today topped Wall Street expectations for the seventh quarter in a row and again raised the earnings forecast for the phenomenally successful medication for age-related macular degeneration , Reuters pointed out. The condition is the most common cause of blindness among older patients, and Eylea?is becoming the preferred treatment. Sales of Eylea soared 153% in the U.S. to $314 million in the first quarter, and the drugmaker is now projecting sales for the year of $1.25 billion to $1.33 billion, slightly above the $1.2 billion to $1.3 billion it had previously put on the table. Sales outside the U.S., where it is partnered with Bayer HealthCare (excluding Japan), were not shabby either. It said they hit $65 million, compared with $19 million in the fourth quarter of 2012, when it was released in international markets. CEO Leonard Schleifer Shares spiked on the good news and were up 6.5%, more than $19, in mid-morning trading, reaching $267.67. The success of Eylea, which has been stealing market share from Roche's ( $RHHBY ) Lucentis , has not only been shared by investors but also by execs at the drugmaker. The executive compensation board handed out more than $140 million in pay, stock and option grants to the top managers last year. CEO Len Schleifer received $30 million of that, but Chief Scientific Officer George Yancopoulos hit the jackpot. His award amounted to $81.5 million in cash, stock and options, including a 500,000-share retention bonus, worth $57.3 million. Separately, the company said it would pay partner Sanofi ( $SNY ) up to $65 million in upfront and milestone payments for full rights to two preclinical programs for its growing business in ophthalmology drugs. – here's the release – read the Reuters story Related Articles: Regeneron execs score $140M payday as Eylea mints money Flush with Eylea sales, Regeneron plots 300-job plant expansion Sanofi lets go of rights to Regeneron's antibodies in ophthalmology Regeneron keeps keeping on with Eylea
Excerpt from:
Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts
Regeneron Pharmaceuticals ( $REGN ) is like a sports team on a streak that keeps bettors in the money by beating bookmaker odds time and again. This streak has gone uninterrupted for nearly two years. The maker of the eye drug Eylea today topped Wall Street expectations for the seventh quarter in a row and again raised the earnings forecast for the phenomenally successful medication for age-related macular degeneration , Reuters pointed out. The condition is the most common cause of blindness among older patients, and Eylea?is becoming the preferred treatment. Sales of Eylea soared 153% in the U.S. to $314 million in the first quarter, and the drugmaker is now projecting sales for the year of $1.25 billion to $1.33 billion, slightly above the $1.2 billion to $1.3 billion it had previously put on the table. Sales outside the U.S., where it is partnered with Bayer HealthCare (excluding Japan), were not shabby either. It said they hit $65 million, compared with $19 million in the fourth quarter of 2012, when it was released in international markets. CEO Leonard Schleifer Shares spiked on the good news and were up 6.5%, more than $19, in mid-morning trading, reaching $267.67. The success of Eylea, which has been stealing market share from Roche's ( $RHHBY ) Lucentis , has not only been shared by investors but also by execs at the drugmaker. The executive compensation board handed out more than $140 million in pay, stock and option grants to the top managers last year. CEO Len Schleifer received $30 million of that, but Chief Scientific Officer George Yancopoulos hit the jackpot. His award amounted to $81.5 million in cash, stock and options, including a 500,000-share retention bonus, worth $57.3 million. Separately, the company said it would pay partner Sanofi ( $SNY ) up to $65 million in upfront and milestone payments for full rights to two preclinical programs for its growing business in ophthalmology drugs. – here's the release – read the Reuters story Related Articles: Regeneron execs score $140M payday as Eylea mints money Flush with Eylea sales, Regeneron plots 300-job plant expansion Sanofi lets go of rights to Regeneron's antibodies in ophthalmology Regeneron keeps keeping on with Eylea
Read the original:
Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts
| © 2011 MSL WORLD |